After-Hours Stock Movers 09/28: (LCID) (CALM) (AFRM) Higher; (LFMD) (EQT) (MU) Lower (more...)
- S&P, Nasdaq enjoy boost from big tech firms, Dow ends a hair lower
- Zillow (ZG) Stock Falls on Report Company Paused Home Purchases due to High Demand, a Temporary Halt Yields a Chance for Competitors Says Analyst
- Oil prices pull back as U.S. factory data intensifies demand concerns
- Chip Shortages are Increasingly Becoming a New Bearish Risk, Inflation Bearish for Consumer Electronics - TFI's Kuo
- Walt Disney (DIS) Stock Slips as Barclays Downgrades Amid Disney+ Growth Slowdown
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
After-Hours Stock Movers:
LifeMD, Inc. ((NASDAQ: LFMD) 8.8% LOWER; announced that it has commenced an underwritten registered public offering of shares of its common stock, par value $0.01 per share. In connection with this offering, the Company expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Lucid Group, (Nasdaq: LCID) 7% HIGHER; kicked off its Production Preview Week, a series of events during which Lucid opened the doors of its Advanced Manufacturing Plant (AMP-1) and Lucid Powertrain Manufacturing (LPM-1) factories in Casa Grande, Arizona, to members of the media and investor communities, policymakers, and Lucid Air Dream Edition customers.
EQT Corporation (NYSE: EQT) 4.9% LOWER; announced the commencement of an underwritten public offering of 25,930,000 shares of its common stock by certain shareholders who received the shares as a part of the Company's acquisition of Alta Resources Development, LLC's upstream and midstream subsidiaries.
Micron Technology (NASDAQ: MU) 4.2% LOWER; reported Q4 EPS of $2.42, $0.10 better than the analyst estimate of $2.32. Revenue for the quarter came in at $8.27 billion versus the consensus estimate of $8.21 billion. Micron Technology sees Q1 2022 EPS of $2.00-$2.30, versus the consensus of $2.61. Micron Technology sees Q1 2022 revenue of $7.85-7.45 billion, versus the consensus of $8.63 billion.
JanOne Inc. (Nasdaq: JAN) 4% LOWER; announced that it is revising its development strategy based on recent communications with the U.S. Food and Drug administration (FDA) for its upcoming clinical trial of lead drug candidate JAN101 as a treatment for Peripheral Artery Disease (PAD). JanOne previously submitted data from the product's Phase 1 and Phase 2a studies showing improved vascular function and a reduction in pain, which was integrated into its Phase 2b protocols and primary and secondary endpoints. The FDA reviewed the data and it provided recommendations and comments on the planned clinical trial to JanOne.
Sherwin-Williams Company (NYSE: SHW) 3.5% LOWER; lowered its Q3 revenue guidance, expecting flat to down slightly compared to the same period last year, and established Q3 EPS in the range of $1.80 to $1.90 which was below the consensus of $2.44. For the full 2021-year the company expects the revenue to be up by a high single digit percentage over 2020, and EPS to be between $7.21 and $7.41, versus the consensus of $9.21.
Cal-Maine Foods (NASDAQ: CALM) 3.3% HIGHER; reported Q1 EPS of ($0.37), $0.33 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $331.7 million versus the consensus estimate of $310.78 million.
Affirm Holdings (NASDAQ: AFRM) 1% HIGHER; to Allow Customers to Buy and Sell Crypto - Bloomberg, Citing CEO
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Stock Movers 10/18: (ETTX) (DRMA) (STLD) Higher; (TASK) (EVER) Lower (more...)
- Stifel's Key Takeaways From Intuitive Surgical's (ISRG) Preliminary PRECISE Trial Data
- Calithera Biosciences (CALA) Acquires Two Clinical-Stage Assets from Takeda Pharmaceuticals
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesAfter-Hours Movers, Definitive Agreement, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!